Moderna, Inc. (MRNA)
NasdaqGS · Price as of · Nasdaq Real Time Price
- Analysts18
- Implied upside-44.4%
- Target range$45.00 to $200.00
- EPS expected-$1.27
- A year ago-$0.51
- Revenue expected$892.4M -12%
- Estimate range-$3.28 to -$0.53
Congress trades in MRNA
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar FL | Sale | $1,001 - $15,000 | |
| 2026-08-19 | Maria Elvira Salazar FL | Purchase | $1,001 - $15,000 | |
| 2026-08-19 | Maria Elvira Salazar FL | Sale | $1,001 - $15,000 |
SEC filings
Moderna news
Tempus AI (TEM) rose 47% on a Merck and Moderna trial. Two analysts upgraded it after the run.
Cantor Fitzgerald initiated Tempus AI (TEM) at overweight with an $80 target, two days after Piper Sandler upgraded it. The 47% run both calls follow came from a Merck and Moderna Phase 3 readout, and the insider sales that made headlines were mostly automatic tax withholding.
Four Korean stocks hit their 30% daily limit on Moderna's cancer-vaccine trial win. Three actually work in mRNA, and the fourth makes semiconductor equipment.
Somagen, Naibec, Genexine and Samyang Biopharm all hit Korea's 30% daily limit on Moderna's cancer-vaccine trial win, and each has a disclosed mRNA business behind it, except one. Entutech hit the same limit riding a five-year-old rumor. It makes semiconductor equipment.
Moderna (MRNA) options bought for a penny Tuesday were worth $96 by Wednesday. That's a one-day gain of 965,200%.
MRNA call options bought for a penny on Tuesday were worth $96 a share by Wednesday, a 965,200% gain in one day, after Moderna's Merck-partnered melanoma vaccine trial succeeded. A $100 bet on them would have been worth $965,300 if sold at the high.
Frequently asked questions
When does MRNA report earnings?
Moderna, Inc. (MRNA) is scheduled to report quarterly results on November 5, 2026, before the open. The 15-analyst consensus is -$1.27 per share on revenue of $892.4M for the quarter ended September 30, 2026, against -$0.51 and $1.02B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.
What do analysts expect for MRNA?
18 analysts cover Moderna, Inc. (MRNA). The consensus rating is Hold. The average price target is $122.67, in a range of $45.00 to $200.00.
Are insiders buying or selling MRNA?
We have no qualifying Form 4 insider purchases or sales on record for Moderna, Inc. (MRNA). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see MRNA SEC filings?
We could not resolve current EDGAR filings for MRNA. This usually means the ticker is a foreign or over-the-counter listing that does not file with the SEC.